Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.

Antiviral therapy - 1 Jan 2012

van Bömmel Florian, Trojan Jörg, Deterding Katja, Wedemeyer Heiner, Wasmuth Hermann E, Hüppe Dietrich, Möller Bernd, Bock Friederike J, Feucht Heinz-Hubert, Berg Thomas

Abstract excerpt

BACKGROUND: Tenofovir disoproxil fumarate (TDF), an acyclic nucleotide analogue was shown to be effective in many HBV-infected patients with resistance to adefovir dipivoxil (ADV). This observation is intriguing because in vitro studies show that HBV mutations selected by ADV confer cross-resistance to TDF. To assess the clinical relevance of this cross-resistance, we studied the evolution of HBV polymerase gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Drug Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Products, pol

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Organophosphonates

Share to Tenofovir

Share to Viremia

Source

Identifiers

PMID: 22892524
DOI: 10.3851/IMP2307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.PMID 22892524Read ↗

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.Semantic proximity Read ↗

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.Semantic proximity Read ↗

A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.Semantic proximity Read ↗

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.Semantic proximity Read ↗

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.Semantic proximity Read ↗

Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.Semantic proximity Read ↗

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Semantic proximity Read ↗

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Semantic proximity Read ↗

Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.Semantic proximity Read ↗

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.